Incyte (INCY) Free Cash Flow (2010 - 2026)
Incyte posted quarterly Free Cash Flow of $359.2 million for Q1 2026, up 36.61% year-on-year from $262.9 million in Q1 2025, and down 26.49% on a QoQ basis from $488.6 million in Q4 2025.
Incyte (INCY) has 17 years of Free Cash Flow data on file, last reported at $359.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 36.61% year-over-year to $359.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 284.64% YoY), and the FY2025 full-year result was $1.4 billion, up 307.11% from the prior year.
- Free Cash Flow for Q1 2026 stood at $359.2 million, down from $488.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $559.3 million in Q3 2025 and bottomed at -$576.0 million in Q2 2024.
- The 5-year median for Free Cash Flow is $262.9 million (2025), against an average of $204.5 million.
- Peak annual rise in Free Cash Flow reached 285.88% in 2024, while the deepest fall reached 292.51% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $336.7 million in 2022, then plunged by 65.77% to $115.3 million in 2023, then soared by 231.58% to $382.2 million in 2024, then climbed by 27.85% to $488.6 million in 2025, then retreated by 26.49% to $359.2 million in 2026.
- The last three Free Cash Flow figures came in at $359.2 million (Q1 2026), $488.6 million (Q4 2025), and $559.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 359.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359.15 Mn |
| Mar 31, 2026 | 359.15 Mn |
| Dec 31, 2025 | 488.59 Mn |
| Dec 31, 2025 | 488.59 Mn |
| Sep 30, 2025 | 559.28 Mn |
| Sep 30, 2025 | 559.28 Mn |
| Jun 30, 2025 | 43.86 Mn |
| Jun 30, 2025 | 43.86 Mn |
| Mar 31, 2025 | 262.90 Mn |
| Mar 31, 2025 | 262.90 Mn |
| Dec 31, 2024 | 382.16 Mn |
| Dec 31, 2024 | 382.16 Mn |
| Sep 30, 2024 | 308.13 Mn |
| Sep 30, 2024 | 308.13 Mn |
| Jun 30, 2024 | -575.98 Mn |
| Jun 30, 2024 | -575.98 Mn |
| Mar 31, 2024 | 218.43 Mn |
| Mar 31, 2024 | 218.43 Mn |
| Dec 31, 2023 | 115.25 Mn |
| Dec 31, 2023 | 115.25 Mn |
| Sep 30, 2023 | 167.07 Mn |
| Sep 30, 2023 | 167.07 Mn |
| Jun 30, 2023 | 299.19 Mn |
| Jun 30, 2023 | 299.19 Mn |
| Mar 31, 2023 | -117.51 Mn |
| Mar 31, 2023 | -117.51 Mn |
| Dec 31, 2022 | 336.73 Mn |
| Dec 31, 2022 | 336.73 Mn |
| Sep 30, 2022 | 268.57 Mn |
| Sep 30, 2022 | 268.57 Mn |
| Jun 30, 2022 | 161.17 Mn |
| Jun 30, 2022 | 161.17 Mn |
| Mar 31, 2022 | 199.98 Mn |
| Mar 31, 2022 | 199.98 Mn |
| Dec 31, 2021 | 234.80 Mn |
| Dec 31, 2021 | 234.80 Mn |
| Sep 30, 2021 | 222.95 Mn |
| Sep 30, 2021 | 222.95 Mn |
| Jun 30, 2021 | 79.82 Mn |
| Jun 30, 2021 | 79.82 Mn |
| Mar 31, 2021 | 184.83 Mn |
| Mar 31, 2021 | 184.83 Mn |
| Dec 31, 2020 | 97.35 Mn |
| Dec 31, 2020 | 97.35 Mn |
| Sep 30, 2020 | 184.10 Mn |
| Sep 30, 2020 | 184.10 Mn |
| Jun 30, 2020 | 293.83 Mn |
| Jun 30, 2020 | 293.83 Mn |
| Mar 31, 2020 | -722.68 Mn |
| Mar 31, 2020 | -722.68 Mn |
| Dec 31, 2019 | 167.64 Mn |
| Dec 31, 2019 | 167.64 Mn |
| Sep 30, 2019 | 287.23 Mn |
| Sep 30, 2019 | 287.23 Mn |
| Jun 30, 2019 | 105.67 Mn |
| Jun 30, 2019 | 105.67 Mn |
| Mar 31, 2019 | 137.40 Mn |
| Mar 31, 2019 | 137.40 Mn |
| Dec 31, 2018 | 124.37 Mn |
| Dec 31, 2018 | 124.37 Mn |
| Sep 30, 2018 | 174.33 Mn |
| Sep 30, 2018 | 174.33 Mn |
| Jun 30, 2018 | 21.61 Mn |
| Jun 30, 2018 | 21.61 Mn |
| Mar 31, 2018 | 8.25 Mn |
| Mar 31, 2018 | 8.25 Mn |
| Dec 31, 2017 | -189.51 Mn |
| Dec 31, 2017 | -189.51 Mn |
| Sep 30, 2017 | 93.82 Mn |
| Sep 30, 2017 | 93.82 Mn |
| Jun 30, 2017 | 86.30 Mn |
| Jun 30, 2017 | 86.30 Mn |
| Mar 31, 2017 | -194.61 Mn |
| Mar 31, 2017 | -194.61 Mn |
| Dec 31, 2016 | 90.38 Mn |
| Dec 31, 2016 | 90.38 Mn |
| Sep 30, 2016 | 176.06 Mn |
| Sep 30, 2016 | 176.06 Mn |
| Jun 30, 2016 | -64.64 Mn |
| Jun 30, 2016 | -64.64 Mn |
| Mar 31, 2016 | 91.97 Mn |
| Mar 31, 2016 | 91.97 Mn |
| Dec 31, 2015 | 65.99 Mn |
| Dec 31, 2015 | 65.99 Mn |
| Sep 30, 2015 | -5.64 Mn |
| Sep 30, 2015 | -5.64 Mn |
| Jun 30, 2015 | 11.19 Mn |
| Jun 30, 2015 | 11.19 Mn |
| Mar 31, 2015 | -8.14 Mn |
| Mar 31, 2015 | -8.14 Mn |
| Dec 31, 2014 | 43.66 Mn |
| Dec 31, 2014 | 43.66 Mn |
| Sep 30, 2014 | 12.33 Mn |
| Sep 30, 2014 | 12.33 Mn |
| Jun 30, 2014 | -23.26 Mn |
| Jun 30, 2014 | -23.26 Mn |
| Mar 31, 2014 | -34.36 Mn |
| Mar 31, 2014 | -34.36 Mn |
| Dec 31, 2013 | -28.73 Mn |
| Dec 31, 2013 | -28.73 Mn |
| Sep 30, 2013 | -12.74 Mn |
| Sep 30, 2013 | -12.74 Mn |
| Jun 30, 2013 | 7.53 Mn |
| Jun 30, 2013 | 7.53 Mn |
| Mar 31, 2013 | 23.84 Mn |
| Mar 31, 2013 | 23.84 Mn |
| Dec 31, 2012 | -22.94 Mn |
| Dec 31, 2012 | -22.94 Mn |
| Sep 30, 2012 | -27.55 Mn |
| Sep 30, 2012 | -27.55 Mn |
| Jun 30, 2012 | 7.72 Mn |
| Jun 30, 2012 | 7.72 Mn |
| Mar 31, 2012 | -54.90 Mn |
| Mar 31, 2012 | -54.90 Mn |
| Dec 31, 2011 | -40.77 Mn |
| Dec 31, 2011 | -40.77 Mn |
| Sep 30, 2011 | -48.16 Mn |
| Sep 30, 2011 | -48.16 Mn |
| Jun 30, 2011 | -31.81 Mn |
| Jun 30, 2011 | -31.81 Mn |
| Mar 31, 2011 | -44.77 Mn |
| Mar 31, 2011 | -44.77 Mn |
| Dec 31, 2010 | 24.66 Mn |
| Dec 31, 2010 | 24.66 Mn |
| Sep 30, 2010 | -29.99 Mn |
| Sep 30, 2010 | -29.99 Mn |
| Jun 30, 2010 | -3.36 Mn |
| Jun 30, 2010 | -3.36 Mn |
| Mar 31, 2010 | 102.52 Mn |
| Mar 31, 2010 | 102.52 Mn |